![CCO Oncology Podcast artwork](https://is5-ssl.mzstatic.com/image/thumb/Podcasts124/v4/3b/39/f2/3b39f298-5635-0bd6-df15-80fecdd32562/mza_3001520250050155739.jpg/100x100bb.jpg)
New Evidence With BTK Inhibitor Therapy in CLL and MCL From SOHO 2023
CCO Oncology Podcast
English - October 04, 2023 15:33 - 20 minutes - 19.3 MBCourses Education Health & Fitness Medicine essential thrombocythemia myelofibrosis oncology cme skin cancer acute myeloid leukemia kidney cancer melanoma gastrointestinal cancer prostate can Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: New Evidence With BTK Inhibitor Therapy in MCL From ICML 2023
In this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at SOHO 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of:
Matching-adjusted indirect comparison of 3 randomized phase III trials of ibrutinib for relapsed/refractory CLL Meta-analysis of cardiovascular adverse events with second-generation BTK inhibitors in CLL BRUIN: updated results of pirtobrutinib in covalent BTK inhibitor–pretreated MCLViPOR: venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide for relapsed/refractory and treatment-naive MCLPresenters:
Catherine C. Coombs, MD, MS
Associate Clinical Professor
Division of Hematology/Oncology, Department of Medicine
UCI Health
Orange, California
Toby Eyre, MBChB, MD
Honorary Senior Lecturer
Hematology and Cancer
University of Oxford
Consultant Hematologist
Department of Hematology
Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom